BTK
Los inhibidores de la tirosina quinasa de Bruton (BTK) son compuestos que específicamente se dirigen e inhiben la BTK, una enzima crucial involucrada en la señalización del receptor de células B y en la regulación de la angiogénesis. La BTK desempeña un papel significativo en la proliferación y supervivencia de las células cancerosas, particularmente en las malignidades hematológicas. Al inhibir la BTK, estos compuestos pueden interrumpir la angiogénesis y el crecimiento tumoral, lo que los convierte en valiosos en la terapia contra el cáncer. En CymitQuimica, ofrecemos una gama de inhibidores de BTK de alta calidad para apoyar su investigación en oncología, inmunología y angiogénesis.
Se han encontrado 165 productos para "BTK".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Tirabrutinib hydrochloride
CAS:Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Fórmula:C25H23ClN6O3Pureza:99.27% - 99.95%Forma y color:SolidPeso molecular:490.94MT-802
CAS:MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Fórmula:C41H41N9O8Pureza:95.93% - 97.60%Forma y color:SolidPeso molecular:787.82Ref: TM-T16157
1mg92,00€5mg177,00€1mL*10mM (DMSO)231,00€10mg269,00€25mg510,00€50mg692,00€100mg888,00€200mg1.251,00€IBT6A
CAS:IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Fórmula:C22H22N6OPureza:99.88% - 99.88%Forma y color:SolidPeso molecular:386.45AS-1763
CAS:AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Fórmula:C33H31FN6O3Pureza:≥95%Forma y color:SolidPeso molecular:578.64Rilzabrutinib
CAS:Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).Fórmula:C36H40FN9O3Pureza:98.28% - 99.76%Forma y color:SolidPeso molecular:665.76Ref: TM-T12542
1mg94,00€5mg222,00€1mL*10mM (DMSO)325,00€10mg356,00€25mg620,00€50mg893,00€100mg1.251,00€500mg2.502,00€ARQ 531
CAS:ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.Fórmula:C25H23ClN4O4Pureza:98.68% - 99.63%Forma y color:SolidPeso molecular:478.93Btk inhibitor 2
CAS:Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Fórmula:C24H25N5O3Pureza:99.94%Forma y color:SolidPeso molecular:431.49Ref: TM-T10629
1mg34,00€2mg49,00€5mg74,00€1mL*10mM (DMSO)82,00€10mg98,00€25mg215,00€50mg356,00€100mg434,00€Acalabrutinib enantiomer
CAS:R-Acalabrutinib, a BTK inhibitor,enantiomer, is researched for cancer, autoimmune diseases, and inflammation.Fórmula:C26H23N7O2Pureza:99.20%Forma y color:SolidPeso molecular:465.51Ref: TM-T67881
200mgA consultar1mg80,00€5mg168,00€1mL*10mM (DMSO)178,00€10mg238,00€25mg379,00€50mg513,00€100mg707,00€Orelabrutinib
CAS:Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).Fórmula:C26H25N3O3Pureza:97.77% - 99.54%Forma y color:SolidPeso molecular:427.49Ref: TM-T12317
1mg86,00€5mg177,00€1mL*10mM (DMSO)205,00€10mg299,00€25mg492,00€50mg682,00€100mg897,00€500mg1.791,00€NRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Fórmula:C43H51N11O6Forma y color:SolidPeso molecular:817.94BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Forma y color:Odour SolidBTK inhibitor 19
CAS:BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Fórmula:C25H24F3N7O3Forma y color:SolidPeso molecular:527.508DD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Fórmula:C55H62N10O8Forma y color:SolidPeso molecular:991.163FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Forma y color:LiquidRef: TM-L1610
1mgA consultar10μL*10mM (DMSO)A consultar20μL*10mM (DMSO)A consultar30μL*10mM (DMSO)A consultar50μL*10mM (DMSO)A consultar100μL*10mM (DMSO)A consultar250μL*10mM (DMSO)A consultarSJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Fórmula:C41H45ClN8O7Pureza:98%Forma y color:SolidPeso molecular:797.3PROTAC BTK Degrader-2
CAS:PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Fórmula:C47H54F2N8O13Forma y color:SolidPeso molecular:976.97Ibrutinib-biotin
CAS:Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Fórmula:C56H80N12O9SPureza:98%Forma y color:SolidPeso molecular:1097.39CNX-500
CAS:CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Fórmula:C48H68N10O9SPureza:98%Forma y color:SolidPeso molecular:961.18TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Forma y color:Odour SolidFDU73
FDU73 is a potent and selective BTK PROTAC degrader with a DC50 of 2.9 nM in JeKo-1 cells. It inhibits tumor cell proliferation and exhibits antitumor activity.Forma y color:Odour Solid
